Welcome to our dedicated page for Nanobiotix S.A. news (Ticker: NBTX), a resource for investors and traders seeking the latest updates and insights on Nanobiotix S.A. stock.
Nanobiotix S.A. (NBTX) is a clinical-stage biotechnology leader developing nanoparticle-enhanced radiotherapy solutions through its proprietary NanoXray platform. This dedicated news hub provides investors and healthcare professionals with essential updates on clinical trials, regulatory developments, and strategic partnerships.
Access timely reports on NBTXR3's progress across multiple cancer types including head and neck tumors and soft tissue sarcoma. Our curated collection features earnings announcements, research milestones, and technology licensing updates that demonstrate Nanobiotix's commitment to advancing precision radiotherapy.
Key content includes trial phase results, manufacturing partnerships, and scientific presentations detailing nanoparticle-enhanced treatment mechanisms. Bookmark this page for structured access to verified information about Nanobiotix's innovative approach to improving radiotherapy outcomes while protecting healthy tissue.
Nanobiotix (NBTX) announced full results from a completed Phase 1 study of JNJ-1900 (NBTXR3) in pancreatic cancer patients. The study, conducted at MD Anderson Cancer Center, showed promising outcomes in patients with locally advanced or borderline resectable pancreatic cancer (n=22). Key findings include:
- Median Overall Survival of 23 months from diagnosis [compared to 19.2 months historical data] - Median Local Progression-Free Survival of 13.3 months from radiation completion - CA19-9 normalization in 59% of patients (vs 17% historical data) - Two LAPC patients achieved R0 surgical resection - Favorable safety profile and injection feasibility
The study has expanded with a new cohort combining JNJ-1900 with standard-of-care concurrent chemoradiation after induction chemotherapy, with the first patient already injected.
Nanobiotix has announced the upcoming presentation of complete results from their Phase 1 study of JNJ-1900 (NBTXR3) in pancreatic cancer patients. The presentation will take place at ESTRO 2025 on May 4th at 11:00 AM EDT, delivered by Principal Investigator Dr. Eugene Koay.
The study focused on patients with locally advanced or borderline resectable pancreatic cancer, conducted at The University of Texas MD Anderson Cancer Center. Following the presentation, Nanobiotix will host a conference call on May 5th at 8:00 AM EDT, featuring CEO Laurent Levy to discuss the findings.
The company, listed on both Euronext (NANO) and NASDAQ (NBTX), is advancing their nanoparticle-based therapeutic approach to expand cancer treatment options. Participants can join the discussion through either a webcast or audio-only option, with the opportunity to submit questions in advance to investors@nanobiotix.com.
Nanobiotix (NBTX) has released its latest voting rights and share capital statement as of March 31, 2025. The company reported 47,426,851 shares outstanding, with 49,193,374 theoretical voting rights and 49,171,256 exercisable voting rights. This disclosure complies with French regulatory requirements, including the French Commercial Code and Financial Markets Authority regulations.
Nanobiotix (NBTX) has reported its full year 2024 financial results and business updates. The company's lead product JNJ-1900 (NBTXR3) continues development in head and neck cancer and lung cancer programs. Key highlights include:
- Cash position of €49.7 million as of December 31, 2024, with runway extended into mid-2026
- Negative revenues of €7.2 million in 2024 (compared to €36.2 million in 2023)
- Net loss increased 72% to €68.1 million (€1.44 per share)
- R&D expenses rose 5% to €40.5 million
- SG&A expenses decreased 7% to €20.5 million
Notable operational progress includes first patient dosing in the Phase 2 CONVERGE study for lung cancer, completion of pancreatic cancer Phase 1 study, and launch of Curadigm platform. The company amended its global licensing agreement with Johnson & Johnson, reducing funding obligations while maintaining milestone payment potential.
Nanobiotix (NASDAQ: NBTX), a late-clinical stage biotechnology company focused on nanoparticle-based cancer treatments, will release its Q4 and full-year 2024 financial results on April 2, 2025, after U.S. market close.
The company will host a conference call and webcast on April 3, 2025, at 8:00 AM EDT / 2:00 PM CEST. CEO Laurent Levy and CFO Bart van Rhijn will present the year-end results and provide a business update for Q4 and full year 2024, followed by a Q&A session.
Nanobiotix (NBTX) has released initial data from a completed Phase 1 dose escalation study evaluating NBTXR3 (JNJ-1900) as a second-line or later therapy for locally advanced non-small cell lung cancer (NSCLC) patients eligible for re-irradiation.
The study, conducted at MD Anderson Cancer Center, demonstrated favorable safety outcomes with no dose-limiting toxicities or Grade 3+ serious adverse events related to NBTXR3. The recommended phase 2 dose was established at 33% of gross tumor volume.
Preliminary survival data from 12 patients showed promising results with:
- 12-month local progression-free survival (LPFS) of 64% (median 18.6 months)
- 12-month overall survival (OS) of 83% (median 30.2 months)
The expansion phase is currently ongoing with 5 out of 12 patients injected to date.
Nanobiotix announced upcoming presentations of data from two Phase 1 studies evaluating JNJ-1900 (NBTXR3) at the 2025 European Lung Cancer Conference (ELCC). The first study, presented by Dr. Saumil Gandhi, focuses on safety and early efficacy signals, including updated local PFS, for re-irradiation with JNJ-1900 in patients with unresectable, locoregional recurrent NSCLC.
The second study, presented by Dr. Colette Shen, evaluates safety and injection feasibility of JNJ-1900 in combination with nivolumab or pembrolizumab for treating patients with lung metastases from NSCLC or other solid tumors. Both presentations are scheduled for March 28th, 2025, at 8:00 AM EDT / 1:00 PM CET.
Nanobiotix (NASDAQ: NBTX) has amended its global licensing agreement with Johnson & Johnson's Janssen Pharmaceutica NV, strengthening its financial position through 2026. Key changes include:
- J&J will now cover most costs for the ongoing NANORAY-312 Phase 3 trial
- Overall deal value adjusted from $2.7B to $2.6B
- Potential milestone payments include:
- $1.77B for first programs including head and neck cancer and lung cancer
- $650M for five new potential indications
- $165M for Asian market developments
- $220M per new indication developed by Nanobiotix
The company maintains tiered double-digit royalties (low 10s to low 20s) and extends cash runway to mid-2026. Nanobiotix expects reduced operational cash burn and is exploring additional non-dilutive financing options to extend runway into 2027.
Nanobiotix (NBTX) has issued a standard regulatory filing regarding its voting rights and share capital in compliance with French regulatory requirements. The announcement was made in accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the French Financial Markets Authority regulations.
The company's shares are listed on both Euronext Paris (Compartment B) and Nasdaq under the ticker symbol NBTX. The company's ISIN code is FR0011341205.
Nanobiotix (NBTX) has released its latest voting rights and shares capital update as of January 31, 2025. The company reported 47,426,851 shares outstanding, with 49,208,659 theoretical voting rights and 49,186,541 exercisable voting rights.
Nanobiotix is a late-stage clinical biotechnology company headquartered in Paris, France, dual-listed on Euronext Paris and Nasdaq Global Select Market. The company specializes in physics-based therapeutic approaches and owns more than 25 patent families across three nanotechnology platforms focusing on oncology, bioavailability and biodistribution, and central nervous system disorders.
FAQ
What is the current stock price of Nanobiotix S.A. (NBTX)?
What is the market cap of Nanobiotix S.A. (NBTX)?
